Wanbury Limited (NSE: WANBURY | BSE: 524212)

By Raveendran R | Updated on:

Source: Wanbury Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)

Metrics for FY 2025-26 Ended Mar 31, 2026
Profit & Loss (₹ Cr)
Revenue
₹650.27 Cr (▲ 8.5%)
Prev Year: ₹599.51 Cr
Gross Profit
₹373.75 Cr (▲ 22.5%)
Prev Year: ₹305.04 Cr
Operating Profit
₹92.45 Cr (▲ 46.7%)
Prev Year: ₹63.01 Cr
Net Profit
₹66.13 Cr (▲ 116.6%)
Prev Year: ₹30.53 Cr
Ratios & Margins (% / x)
Gross Margin
57.48 % (▲ 659 bps)
Prev Year: 50.88 %
Operating Margin
14.22 % (▲ 371 bps)
Prev Year: 10.51 %
PAT Margin
10.17 % (▲ 508 bps)
Prev Year: 5.09 %
ROCE
29.20 % (▲ 287 bps)
Prev Year: 26.33 %
ROE
45.78 % (▼ 573 bps)
Prev Year: 51.51 %
ROA
12.77 % (▲ 540 bps)
Prev Year: 7.38 %
Asset Turnover
1.26x (▼ 0.19 pts)
Prev Year: 1.45x
Balance Sheet (₹ Cr)
Total Assets
₹517.67 Cr (▲ 25.1%)
Prev Year: ₹413.92 Cr
Current Assets
₹238.56 Cr (▲ 23.4%)
Prev Year: ₹193.32 Cr
Total Liabilities
₹373.22 Cr (▲ 5.2%)
Prev Year: ₹354.64 Cr
Current Liabilities
₹201.04 Cr (▲ 15.1%)
Prev Year: ₹174.61 Cr
Total Debt
₹215.45 Cr (▲ 24.4%)
Prev Year: ₹173.23 Cr
Total Equity
₹144.45 Cr (▲ 143.7%)
Prev Year: ₹59.27 Cr
Working Capital
₹37.52 Cr (▲ 100.5%)
Prev Year: ₹18.71 Cr
Ratios & Margins (% / x)
Current Ratio
1.19x (▲ 0.08 pts)
Prev Year: 1.11x
Debt to Equity
1.49x (▼ 1.43 pts)
Prev Year: 2.92x
Debt to Assets
0.42x (- 0.00 pts)
Prev Year: 0.42x
Equity Multiplier
3.58x (▼ 3.40 pts)
Prev Year: 6.98x
Cash Flow (₹ Cr)
Operating Cash Flow
₹31.53 Cr (▲ 20.3%)
Prev Year: ₹26.20 Cr
CapEx
₹59.06 Cr (▲ 20.5%)
Prev Year: ₹49.03 Cr
Free Cash Flow
-₹27.53 Cr (▼ 20.6%)
Prev Year: -₹22.83 Cr
Ratios & Margins (% / x)
FCF Margin
-4.23 % (▼ 43 bps)
Prev Year: -3.81 %
Cash ROCE
9.96 % (▼ 99 bps)
Prev Year: 10.95 %
Cash ROE
21.83 % (▼ 2238 bps)
Prev Year: 44.20 %
CF to Debt
0.15x (- 0.00 pts)
Prev Year: 0.15x

📋 Quick Facts: Wanbury Snapshot & Key Takeaways

  • Core Business & Market Position: Wanbury Limited is an established Indian pharmaceutical corporation operating across Active Pharmaceutical Ingredients (API) and Domestic Branded Formulations. It ranks as the world’s largest manufacturer of Metformin Hydrochloride (commanding approximately 10% global market share) and holds roughly 30% of global market share in Sertraline Hydrochloride, alongside leadership in Tramadol Hydrochloride exports and a dominant 75% market share for Sertraline in Brazil.
  • FY26 Financial Trajectory: Revenue from operations expanded by 8.47% YoY to ₹650.27 Crores in FY 2025-26 (compared to ₹599.51 Crores in FY 2024-25). Net Profit After Tax (PAT) surged by 116.62% YoY to ₹66.13 Crores (from ₹30.53 Crores in FY 2024-25), driven by manufacturing efficiency improvements, lower finance charges, and operational turnaround.
  • Key Growth Catalyst: Successful regional commercialisation of Wanbury C-RED (liposomal iron formulation) and pediatric brand extensions Coriminic CPM Drops and Coriminic NS Nasal Drops. In APIs, commercial shipment of high-demand Anaesthetic API commenced in January 2026, accompanied by new regulatory approvals (ANVISA Form II Sertraline, South Korea MFDS zero-observation clearance, and Australian TGA audit completion).
  • Primary Balance Sheet / Operational Watchpoint: Total borrowings expanded to ₹215.45 Crores as of March 31, 2026 (up from ₹173.23 Crores as of March 31, 2025), driven by working capital drawdowns and short-term debt of ₹68.30 Crores. Although borrowing costs reduced substantially from ~21% to 12.5% per annum, long-term debt servicing requires consistent operating cash generation.
Attribute Disclosed Detail
Official Company Name Wanbury Limited
Corporate Identity Number (CIN) L51900MH1988PLC048455
ISIN INE107F01022
Stock Exchange Listing BSE Limited: 524212 | National Stock Exchange of India Limited: WANBURY
Founding Year / Incorporation Date Incorporated on April 6, 1988 (Commenced 38th AGM cycle in 2026)
Registered Office & Corporate Headquarters BSEL Tech Park, B-Wing, 10th Floor, Sector 30-A, Opposite Vashi Railway Station, Vashi, Navi Mumbai – 400 703, Maharashtra, India
Telephone & Official IR Email Tel: +91-22-6794 2222 / +91-22-7196 3222 | Email: cs@wanbury.com / info@wanbury.com
Executive Leadership Mr. K. Chandran (Chairman & Whole-time Director) | Mr. Mohan Kumar Rayana (Whole-time Director)
Key Managerial Personnel (KMP) Mr. Vinod Verma (Chief Financial Officer) | Mr. Jitendra J. Gandhi (Company Secretary & Compliance Officer)
Promoter Entities Expert Chemicals (India) Private Limited (34.36%) & Kingsbury Investments Inc. (8.66%)
Industry / Sector Classification Pharmaceuticals (Active Pharmaceutical Ingredients & Finished Dosage Formulations)
Total Permanent Employees 1,200 permanent employees on payroll as of March 31, 2026
Manufacturing Footprint 2 multi-purpose USFDA-inspected API manufacturing facilities located at Patalganga (Maharashtra) and Tanuku (Andhra Pradesh)
Credit Rating Programme Company does not have an active credit rating programme (no fixed deposit mobilise schemes)
Statutory Auditors M/s. Kapoor & Parekh Associates, Chartered Accountants, Mumbai (Firm Registration No. 104803W)
Secretarial Auditor Ms. Kala Agarwal, Practising Company Secretary (FCS No. 5976, COP No. 5356)
Cost Auditor M/s. Manish Shukla & Associates (FY 2025-26) | M/s. ABK & Associates (FY 2026-27 appointment)
Registrar & Share Transfer Agent (RTA) M/s. Purva Sharegistry (India) Private Limited, Lower Parel (East), Mumbai – 400 011, Maharashtra

🏢 The Corporate Identity: Wanbury Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Wanbury Limited operates an integrated, dual-engine pharmaceutical business model anchored by global scale in Active Pharmaceutical Ingredients (APIs) and supported by a targeted domestic branded formulations business in India. Over three decades of chemical synthesis and regulatory compliance have established Wanbury as an indispensable bulk drug supplier to multi-national pharmaceutical corporations across regulated markets, including the United States, the European Union, Brazil, South Korea, and Australia.

In the API segment, Wanbury focuses on high-volume, chemistry-intensive synthetic molecules where cost leadership, process engineering, and stringent regulatory compliance erect massive entry barriers. The company manufactures its core molecules in dedicated facilities with cumulative reactor volume of approximately 500 KL, enabling it to maintain an estimated 10% global market share in Metformin Hydrochloride and roughly 30% in Sertraline Hydrochloride. In the domestic formulations vertical, Wanbury leverages its field force of medical representatives to market specialized branded prescription medicines across gynecology, pediatrics, general medicine, and chronic disease therapies.

The Founders, Promoters & Their Legacy

Wanbury is led by promoter-directors who possess deep domain experience across pharmaceutical manufacturing, bulk chemical synthesis, and international regulatory frameworks. Mr. K. Chandran, Chairman and Whole-time Director, has been associated with Wanbury since 1990 and was formally inducted to the Board of Directors in January 2001. His leadership over three decades guided the transition of the company into an internationally recognized bulk API supplier.

Mr. Mohan Kumar Rayana, Whole-time Director, holds a Bachelor of Pharmacy degree from the University of Mumbai and has been associated with Wanbury in advisory and management capacities for over 25 years before his appointment to the Board in July 2023. Together with promoter investment vehicles Expert Chemicals (India) Private Limited and Kingsbury Investments Inc., the leadership has driven strategic debt restructuring, operational turnarounds, and modernization across both manufacturing facilities.

The Journey: Corporate History & Key Milestones

Incorporated in April 1988 under the Indian Companies Act, Wanbury transitioned through multiple business cycles, transforming from a domestic producer into an export powerhouse. The company achieved initial prominence through bulk synthesis of anti-diabetic molecules, establishing itself as India’s foremost producer and exporter of Metformin Hydrochloride.

Strategic capacity debottlenecking, process chemistry R&D, and global regulatory filings accelerated international expansion over the subsequent decades. Key historical milestones leading to the current fiscal year include:

  • Global Regulatory Verifications: Clearance of USFDA audits at the Patalganga facility with zero Form 483 observations, followed by ANVISA (Brazil FDA) clearance at the Tanuku site with zero observations.
  • ERP Transformation: Cutover from legacy SAP ECC to SAP S/4HANA Enterprise Resource Planning (“Rise with SAP”) on October 3, 2025, supported by Deloitte as implementation partner.
  • Commercial Milestones: Achieving initial commercial shipments of high-demand Anaesthetic API on January 30, 2026, and securing ANVISA approval for Sertraline Form II in Brazil.
  • Balance Sheet Rationalisation: Successful conversion of 20,00,000 preferential convertible warrants on September 18, 2025, injecting ₹24.00 Crores of equity and share premium into the business.

The Corporate Umbrella & Group Structure

Historically, Wanbury maintained offshore direct and indirect subsidiaries to facilitate international trading and clinical development, including Wanbury Holdings B.V. (Netherlands), Ningxia Wanbury Fine Chemicals Co. Ltd. (China), Wanbury Global FZE (UAE), and Cantabria Pharma S.L. (Spain). Because these foreign entities had remained inoperative for several years and their carrying values had already been 100% impaired, the Board approved formal deregistration.

All four overseas subsidiaries were formally deregistered in their respective legal jurisdictions effective April 1, 2025. Consequently, Wanbury Limited operates as a clean standalone operating entity with zero active operating subsidiaries, associates, or joint ventures as of March 31, 2026.

⚙️ The Business Engine: Wanbury Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

Wanbury manages its operational architecture as a single unified primary segment: “Pharmaceuticals and related products”, pursuant to Ind AS 108. However, internal management tracking and operational reporting divide performance into two dynamic business engines: Active Pharmaceutical Ingredients (API) and Domestic Formulations.

Business Division Revenue (₹ in Crores) % Share of Operational Revenue Operational Growth & Margin Dynamics
Active Pharmaceutical Ingredients (API) 574.00 88.27% Grew 8% YoY; ~80% export-focused across US, EU, and Brazil; supported by 500 KL reactor capacity
Domestic Branded Formulations 76.93 11.83% Restructured field force productivity; focused on gynecology and pediatric prescription generation
Other Operating Revenue 6.36 0.98% Comprises export incentives (₹0.22 Cr), scrap sales (₹0.48 Cr), and net foreign exchange gains (₹5.65 Cr)
Total Revenue from Operations 650.27 100.00% Overall operational expansion of 8.47% YoY against ₹599.51 Crores in FY 2024-25

The API division generated ₹574.00 Crores, capturing 88.27% of operational revenue. Export markets absorbed roughly 80% of API output, driven by resilient bulk demand for anti-diabetic and anti-depressant molecules across regulated Western and Latin American territories. Stable raw material pricing, process re-engineering, and uninterrupted supply chains generated healthy gross margins across bulk contracts.

The Domestic Formulations business contributed ₹76.93 Crores, representing 11.83% of sales. The division underwent comprehensive field-force restructuring during FY 2025-26, implementing GPS-based territory management, disciplined doctor-engagement protocols, and new product introductions tailored to regulatory shifts in pediatric care.

The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)

Wanbury’s commercialized API portfolio comprises high-volume synthetic molecules manufactured under strict cGMP protocols. The company’s lead products are:

  • Metformin Hydrochloride (and Metformin HCl Direct Compression Grade): World-leading anti-diabetic API. Capacity expanded by approximately 18% over the past three years through engineering debottlenecking, driving 7% volume growth in direct compression grades.
  • Sertraline Hydrochloride: Major anti-depressant molecule. Installed capacity debottlenecked by approximately 35% over three years; supported by regulatory approvals for Form I and Form II.
  • Tramadol Hydrochloride: Centrally acting synthetic opioid analgesic exported globally under stringent controlled-substance compliance protocols.
  • Mefenamic Acid: Non-steroidal anti-inflammatory drug (NSAID) with widespread therapeutic adoption.
  • Diphenhydramine Citrate & Diphenhydramine Hydrochloride: High-purity anti-histaminic agents.
  • Paroxetine Hydrochloride: Selective serotonin reuptake inhibitor (SSRI) addressing psychiatric conditions.
  • Anaesthetic API: New high-demand molecule launched commercially on January 30, 2026, with rapid production scale-up underway.

In accordance with Ind AS 108 disclosures, Wanbury maintains a healthy customer diversification profile: no single customer accounts for 10% or more of total corporate revenue, protecting the enterprise from concentrated credit or off-take shocks. Installed manufacturing capacity spans 500 KL of reactor volume, with identified engineering potential for an additional 100 KL of brownfield expansion.

The Names You Know: Key Brands & Flagship Portfolio

In the domestic branded formulations space, Wanbury concentrates on niche therapeutic categories, serving pediatricians, gynecologists, and consulting physicians.

Brand / Product Name Category / Business Segment Target Market & Key Positioning
Wanbury C-RED Hematinic / Anemia Management Next-generation Liposomal Iron (ferric pyrophosphate) formulation fortified with Vitamin C, B12, and Folic Acid; provides superior gastrointestinal tolerability without metallic aftertaste or constipation; targets pregnant women and iron-deficient patients.
Coriminic CPM Drops Pediatric Cold & Allergy Relief Chlorpheniramine Maleate mono-formulation without systemic decongestants, formulated to comply with DCGI directives restricting fixed-dose cold combinations in children below 4 years of age.
Coriminic NS Nasal Drops Pediatric Respiratory Decongestant Normal Saline isotonic non-systemic nasal drops delivering localized pediatric relief from nasal congestion, allowing physicians to navigate regulatory guidelines safely.

The launch of Wanbury C-RED marks the company’s return to the domestic hematinic market following the divestment of its legacy C-Pink brand. Commercialization started regionally in North and South India, with phased pan-India distribution underway. The Coriminic brand extensions proactively addressed the Indian Drug Controller General’s (DCGI) safety advisories on pediatric fixed-dose combinations, capturing market share within India’s estimated ₹80 Crore liquid cold preparation category.

Mapping the Domestic & Global Reach (India vs. Exports)

Wanbury serves pharmaceutical markets in over 50 countries, with regulated jurisdictions accounting for the vast majority of international revenue.

Geographic Market Revenue (₹ in Crores) % Share of Total Revenue Key Territories & Operational Dynamics
India (Domestic Market) 174.49 27.09% Encompasses domestic API deliveries and pan-India branded formulations distribution
Brazil 90.71 14.09% Dominant market position; 75% market share in Sertraline API; supported by ANVISA approvals
Rest of the World (Exports) 378.71 58.82% Regulated customer shipments across the United States, European Union, South Korea, and Australia
Total Revenue from External Customers 643.91 100.00% Customer revenue net of non-sales operating items; 72.91% derived from international exports

International shipments delivered ₹469.42 Crores, representing 72.91% of sales. Brazil represents a core geographic bastion, contributing ₹90.71 Crores. Wanbury controls an estimated 75% market share for Sertraline in Brazil, reinforced by ANVISA clearances for both Form I and Form II crystal structures. Regulated European and North American markets generate steady contract cash flows through established partnerships with tier-1 generic pharmaceutical manufacturers.

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

Wanbury operates two multi-purpose synthetic API manufacturing sites built in accordance with international cGMP standards:

  • Patalganga Facility (Plot No. A-15, MIDC Industrial Area, Raigad District, Maharashtra): Specialises in high-volume synthesis of Metformin Hydrochloride, specialty direct-compression grades, and active chemical intermediates. Inspected by the USFDA (zero Form 483 observations in June 2024), ANVISA (CBPF GMP certificate issued), and South Korea’s MFDS (cleared with zero observations in April 2026).
  • Tanuku Facility (K. Illindalaparru Village, Tanuku, West Godavari District, Andhra Pradesh): Focuses on central nervous system (CNS) molecules, Sertraline Hydrochloride, Tramadol, and high-demand Anaesthetic APIs. Completed ANVISA inspections with zero observations and successfully cleared Australia’s TGA quality inspection in June 2026.
  • Corporate & Administrative Headquarters: BSEL Tech Park, B-Wing, 10th Floor, Vashi, Navi Mumbai, Maharashtra.

📊 The Financial Health: Wanbury Financial Statements & Numbers Simplified

The following financial statements reflect the performance and financial position of Wanbury Limited under Indian Accounting Standards (Ind AS) for the fiscal years ended March 31, 2026 and March 31, 2025.

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

Particulars (Statement of Profit & Loss) FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Revenue from Operations 650.27 599.51 +8.47%
Other Income 0.94 3.49 -73.07%
Total Income 651.21 603.01 +7.99%
Cost of Materials Consumed 272.90 277.88 -1.79%
Purchases of Stock-in-Trade 16.62 15.08 +10.21%
Changes in Inventories of Finished Goods, Stock-in-Trade and WIP -13.00 1.51 N/M
Employee Benefits Expense 119.64 101.56 +17.80%
Finance Costs 29.98 36.95 -18.86%
Depreciation and Amortisation Expense 14.31 13.41 +6.71%
Other Expenses 147.37 127.07 +15.98%
Total Expenses 587.80 573.46 +2.50%
Operating Profit (EBIT) 92.45 63.01 +46.72%
EBITDA 106.76 76.42 +39.70%
Profit Before Exceptional Items & Tax 63.41 29.55 +114.59%
Exceptional Items: New Labour Codes Provision -3.60 0.00 N/M
Profit Before Tax (PBT) 59.80 29.55 +102.37%
Current Tax Expense (including prior periods) 0.65 5.86 -88.91%
Deferred Tax (Credit) / Charge -6.98 -6.84 +2.05%
Total Tax Expense -6.33 -0.98 +545.92%
Profit for the Year (PAT) 66.13 30.53 +116.61%
Other Comprehensive Income / (Loss) (Net of Tax) -0.55 -0.37 +48.65%
Total Comprehensive Income for the Year 65.59 30.16 +117.47%
Basic Earnings Per Share (EPS) before exceptional items (₹) 20.55 9.32 +120.49%
Basic Earnings Per Share (EPS) after exceptional items (₹) 19.49 9.32 +109.12%
Diluted Earnings Per Share (EPS) after exceptional items (₹) 19.42 8.98 +116.26%

Revenue from operations grew by 8.47% to ₹650.27 Crores during FY 2025-26, compared to ₹599.51 Crores in FY 2024-25. Operating Profit (EBIT) expanded from ₹63.01 Crores to ₹92.45 Crores, representing an Operating Margin of 14.22% (up from 10.51% in FY 2024-25). This operational expansion was underpinned by raw material cost control (material costs declined to ₹272.90 Crores despite higher production volumes) and a ₹6.97 Crore decline in finance costs.

Net profit after tax rose to ₹66.13 Crores compared to ₹30.53 Crores in the preceding fiscal year. Exceptional items of ₹3.60 Crores reflect an actuarial provision for incremental gratuity and leave obligations arising from the consolidation of Indian labour statutes into the New Labour Codes effective November 21, 2025.

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

Particulars (Balance Sheet as at March 31) FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Non-Current Assets
Property, Plant and Equipment 210.26 189.69 +10.84%
Capital Work-in-Progress (CWIP) 25.42 5.38 +372.49%
Other Intangible Assets 2.71 0.23 +1078.26%
Right of Use Assets (Leasehold Land & Premises) 16.25 10.81 +50.32%
Non-Current Financial Investments 0.03 0.02 +50.00%
Other Non-Current Financial Assets 3.96 4.04 -1.98%
Deferred Tax Assets (Net) 14.20 7.04 +101.70%
Income Tax Assets (Net) 1.73 1.44 +20.14%
Other Non-Current Assets 4.55 1.96 +132.14%
Total Non-Current Assets 279.11 220.60 +26.52%
Current Assets
Inventories 50.63 37.68 +34.37%
Current Investments 0.00 0.13 -100.00%
Trade Receivables 143.28 114.16 +25.51%
Cash and Cash Equivalents 1.61 4.06 -60.34%
Bank Balances Other than Cash & Cash Equivalents 6.02 8.77 -31.36%
Other Current Financial Assets 2.70 2.10 +28.57%
Other Current Assets 34.32 26.42 +29.90%
Total Current Assets 238.56 193.32 +23.40%
TOTAL ASSETS 517.67 413.92 +25.07%
Equity
Equity Share Capital 34.94 32.77 +6.62%
Other Equity 109.51 26.50 +313.25%
Total Equity (Net Worth) 144.45 59.27 +143.72%
Non-Current Liabilities
Non-Current Borrowings (Unlisted Secured NCDs & Vehicle Loans) 147.15 160.29 -8.20%
Non-Current Lease Liabilities 2.21 0.82 +169.51%
Other Non-Current Financial Liabilities 2.39 1.47 +62.59%
Non-Current Provisions (Gratuity & Leave Benefits) 20.44 17.45 +17.13%
Total Non-Current Liabilities 172.18 180.03 -4.36%
Current Liabilities
Current Borrowings (Working Capital, Factoring & Current Maturities of NCDs) 68.30 12.94 +427.82%
Trade Payables – Micro & Small Enterprises 6.75 3.98 +69.60%
Trade Payables – Other Creditors 100.49 134.48 -25.28%
Current Lease Liabilities 6.71 2.87 +133.80%
Other Current Financial Liabilities 3.55 6.08 -41.61%
Other Current Liabilities 10.50 11.71 -10.33%
Current Provisions 4.73 2.56 +84.77%
Total Current Liabilities 201.04 174.61 +15.14%
Total Liabilities 373.22 354.64 +5.24%
TOTAL EQUITY AND LIABILITIES 517.67 413.92 +25.07%

Total Equity (Net Worth) expanded to ₹144.45 Crores as of March 31, 2026, compared to ₹59.27 Crores on March 31, 2025. This strengthening reflects retained earnings accretion of ₹66.13 Crores alongside the conversion of 20,00,000 share warrants, which contributed ₹2.00 Crores to equity capital and ₹22.00 Crores to securities premium.

Total Borrowings (Non-Current Borrowings of ₹147.15 Crores plus Current Borrowings of ₹68.30 Crores) stood at ₹215.45 Crores. Current borrowings increased primarily because ₹40.00 Crores of unlisted secured NCDs were reclassified under current maturities, maturing within the next 12-month period.

Working Capital Cycle & Schedule III Statutory Ratio Explanations

Analytical Ratio FY 2025-26 FY 2024-25 % Variance Operational Dynamics & Disclosed Cause of Variance Latest YoY (%)
Current Ratio (in times) 1.19 1.11 7.21% Working capital health remained stable with current assets exceeding current obligations. +7.21%
Debt-Equity Ratio (in times) 1.57 3.02 -48.05% Improved substantially due to higher profitability, equity addition from warrant conversion, and debt repayments. -48.01%
Debt Service Coverage Ratio (DSCR) (in times) 2.63 2.12 24.26% Bolstered by higher operational cash flows and reduced average finance costs. +24.06%
Return on Equity (ROE) (%) 45.78% 51.51% -2.21% Remained resilient above 68% despite a significantly expanded equity capital base. –
Inventory Turnover Ratio (in times) 6.26 7.99 -21.65% Reflects higher inventory build-up of finished goods and WIP ahead of commercial roll-outs. -21.65%
Trade Receivables Turnover Ratio (in times) 5.05 5.91 -14.55% Reflects expanding export sales on 60 to 90-day credit tenures. -14.55%
Trade Payables Turnover Ratio (in times) 2.36 1.97 19.80% Improved settlement discipline with active API raw material vendors. +19.80%
Net Capital Turnover Ratio (in times) 17.33 31.84 -45.57% Lower net capital turnover resulted from a larger working capital base employed during the year. -45.57%
Net Profit Ratio (%) 10.72% 5.09% 110.61% Doubled YoY due to operational leverage, raw material cost savings, and reduced interest burdens. –
Return on Capital Employed (ROCE) (%) 29.20% 26.33% -9.99% Remained strong across manufacturing operations despite heavy capital expenditure additions. –
Return on Investment (ROI) (%) 10.77% 122.06% -111.29% Normalized downwards following the redemption of short-term mutual fund liquid investments. –

Cash Flow: Tracking the Money Movement

Particulars (Cash Flow Statement) FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Net Profit Before Exceptional Items and Tax 63.41 29.55 +114.59%
Total Non-Cash & Working Capital Adjustments 45.50 48.08 -5.37%
Operating Profit Before Working Capital Changes 108.91 77.63 +40.29%
Net (Increase) / Decrease in Working Capital Assets & Liabilities -76.44 -51.06 +49.71%
Direct Taxes Paid (Net of Refunds) -0.94 -0.37 +154.05%
Net Cash Generated from Operating Activities 31.53 26.20 +20.34%
Purchase of Property, Plant and Equipment (CapEx & Advances) 59.06 49.03 +20.46%
Proceeds from Sale of Fixed Assets & Investments 29.20% 26.33% –
Interest Received & Bank Term Deposits Matured / (Placed) 3.34 -2.78 N/M
Net Cash Used in Investing Activities -56.40 -51.17 +10.22%
Proceeds from Issue of Equity Shares & Warrants 29.20% 26.33% –
Net Proceeds / (Repayment) of Borrowings 29.20% 26.33% –
Interest and Finance Charges Paid -29.46 -34.74 -15.20%
Principal & Interest Lease Liability Payments -3.79 -3.48 +8.91%
Net Cash Generated from Financing Activities 22.42 25.63 -12.52%
Net Increase / (Decrease) in Cash and Cash Equivalents -2.45 0.66 N/M
Cash and Cash Equivalents at Beginning of the Year 4.06 3.40 +19.41%
Cash and Cash Equivalents at End of the Year 1.61 4.06 -60.34%

Operating cash flows grew by 20.34% to ₹31.53 Crores during FY 2025-26, supported by an operating cash surplus before working capital changes of ₹108.91 Crores. This cash generation supported a ₹59.06 Crore capital expenditure program aimed at plant debottlenecking, chiller upgrades, automated reactor control lines, and ERP digitalization.

Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange

Wanbury directed substantial internal capital towards production debottlenecking and process optimization across both operational manufacturing sites during FY 2025-26:

  • Tanuku Site Infrastructure: Completed installation of a 33KV High Tension dedicated power line, lowering unit energy costs by 45 paise per unit. Commissioned an additional 2,000 KVA transformer for balanced plant load distribution, installed a 4,000 Amps PCC panel, and upgraded boiler condensate recovery to 30%, committing ₹4.41 Crores to energy conservation equipment.
  • Patalganga Site Upgrades: Installed a new 800 TR cooling tower, a 125 TR water chiller to improve methanol solvent recovery to 78%, and commissioned a 4 TPH steam boiler with changeover panels, reducing maintenance shutdown windows from 8 hours to 2 hours. Capital expenditure on energy efficiency and reactor improvements totaled ₹4.32 Crores.
  • Capital Work-in-Progress (CWIP): CWIP stood at ₹25.42 Crores as of March 31, 2026, comprising process automation and crystallization projects scheduled for phased commissioning within 12 months.
  • Net Foreign Exchange Earnings: Wanbury remained a significant net foreign exchange earner. Export earnings totaled ₹475.87 Crores (FOB value of ₹463.20 Crores plus freight and insurance of ₹12.67 Crores) against foreign exchange expenditures of ₹83.02 Crores (including raw material imports of ₹74.42 Crores), generating a net foreign exchange surplus of ₹392.85 Crores.

👥 Power & Control: Wanbury Governance, Leadership & Shareholding Pattern

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

Wanbury’s Board of Directors comprises six directors, half of whom are Independent Non-Executive Directors. This structure ensures oversight across strategic planning, financial compliance, and operational governance.

Name of Director / KMP Designation / Role DIN Category
Mr. K. Chandran Chairman & Whole-time Director 00005868 Executive / Whole-time Director
Mr. Mohan Kumar Rayana Whole-time Director 07878975 Executive / Promoter Whole-time Director
Dr. Anupama Vaidya Director 02713517 Non-Executive Independent Woman Director
Mr. Mridul S. Mehta Director (Audit Committee Chairman) 10177545 Non-Executive Independent Director
Mr. Manojkumar K. Gursahani Director (Stakeholders Committee Chairman) 01064558 Non-Executive Independent Director
Mr. P. V. Sankar Dass Director (Risk Management Committee Chairman) 06604217 Non-Executive Independent Director
Mr. Vinod Verma Chief Financial Officer (CFO) – Key Managerial Personnel
Mr. Jitendra J. Gandhi Company Secretary & Compliance Officer – Key Managerial Personnel

Governance mechanisms were reinforced during the fiscal year. The Board held seven formal meetings. Committee structures were regularized following exchange communications, and penalty adjustments totaling ₹0.0070 Crores for Regulation 17(1) and ₹0.0028 Crores for Regulation 19 were paid. Remuneration paid to Whole-time Directors totaled ₹2.81 Crores (Mr. Mohan Kumar Rayana received ₹1.61 Crores including ₹0.11 Crores in perquisites, and Mr. K. Chandran received ₹1.20 Crores).

Who Owns the Stock? Shareholding Pattern

As of March 31, 2026, the company’s paid-up equity share capital stood at ₹34.94 Crores, divided into 3,49,39,398 equity shares of face value ₹10 each.

Category of Shareholder Number of Shares Held % of Total Equity Capital
Promoter & Promoter Group 1,50,29,561 43.02%
Expert Chemicals (India) Private Limited 1,20,05,561 34.36%
Kingsbury Investments Inc. 30,24,000 8.66%
Institutional Investors 2,06,561 0.59%
Mutual Funds, UTI, Banks & Insurance Entities 1,416 0.00%
Foreign Institutional Investors (FIIs / FPIs) 2,05,145 0.59%
Public & Non-Institutional Shareholders 1,97,03,276 56.39%
Indian Public Individuals 1,48,68,462 42.55%
Private Bodies Corporate 21,41,306 6.13%
NRIs / Overseas Corporate Bodies 5,89,354 1.69%
Investor Education and Protection Fund (IEPF) 3,38,465 0.97%
Clearing Members / HUF / LLPs / Foreign Corporates 17,65,689 5.05%
Total Issued & Subscribed Equity Capital 3,49,39,398 100.00%

Promoter holding expanded from 39.76% to 43.02% during FY 2025-26 following the preferential allotment of 20,00,000 equity shares upon conversion of warrants held by Expert Chemicals (India) Private Limited. Public dematerialization stands at 99.36%, with 3,47,17,272 shares held in electronic form through NSDL and CDSL.

🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

Pursuant to Section 129(3) read with Rule 5 of the Companies (Accounts) Rules, 2014, Form AOC-1 confirms that Wanbury Limited had no active operating subsidiaries, associates, or joint venture entities as of March 31, 2026.

Entity Name Relationship Country of Incorporation % Equity Holding Operational Status & Financial Impact
Wanbury Holdings B.V. Subsidiary Netherlands 100.00% Inoperative; fully derecognised and struck off on April 1, 2025; nil financial impact.
Ningxia Wanbury Fine Chemicals Co. Ltd. Subsidiary China 100.00% Inoperative; struck off on April 1, 2025; full impairment recognized in earlier years.
Wanbury Global FZE Subsidiary United Arab Emirates 100.00% Inoperative; struck off on April 1, 2025; zero financial impact on Profit & Loss.
Cantabria Pharma S.L. Step-down Subsidiary Spain 100.00% In liquidation; deregistered on April 1, 2025; carrying value previously written down.

Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities

Wanbury maintains modest strategic investments, including 1800 quoted equity shares in Bank of India (valued at ₹0.02 Crores) and unquoted cooperative bank shares. The company does not participate in any commercial paper or external credit rating programme, funding capital requirements through bank consortia and structured debentures.

Working capital and structured debt facilities are primarily provided by SBM Bank (India) Limited and Emerging India Credit Opportunities Fund II. Bank credit facilities are secured against hypothecation of current assets, first pari-passu mortgage over immovable properties at Tanuku, corporate guarantees, and a personal guarantee from Director Mr. K. Chandran.

Contingent liabilities and legal exposures as of March 31, 2026, disclosed under Note 44, include:

  • Direct & Indirect Tax Demands: Disputed income tax demands of ₹30.45 Crores (net of ₹0.13 Crores paid under protest), disputed GST demands of ₹30.52 Crores (with ₹0.21 Crores paid under protest), disputed sales tax claims of ₹0.43 Crores, and disputed service tax claims of ₹1.86 Crores.
  • Unfulfilled Export Obligations: Custom duty liability under the Advance License Scheme pending export fulfillment amounting to ₹30.83 Crores.
  • Commercial & NPPA Claims: Claims against the company not acknowledged as debts totaling ₹26.36 Crores, alongside a disputed price demand of ₹1.91 Crores from the National Pharmaceutical Pricing Authority (NPPA).
  • Capital Commitments: Estimated contracts remaining to be executed on capital accounts (net of advances) stood at ₹16.57 Crores (compared to ₹1.21 Crores in FY 2024-25).

🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs

Competitive Advantages & Economic Moats

Wanbury’s operating model is reinforced by significant barriers to entry in synthetic chemical APIs:

  • Global Scale & Cost Leadership: Controlling ~10% of global Metformin volume and ~30% of global Sertraline volume provides raw material purchasing leverage and fixed-overhead absorption that lower-tier competitors cannot easily match.
  • Regulatory Assets: Maintaining zero-observation inspection records with the USFDA, ANVISA (Brazil), MFDS (South Korea), and TGA (Australia) creates high switching costs for pharmaceutical formulations customers who face lengthy DMF filing requirements if they change suppliers.
  • Specialized Process Chemistry: Patented process innovations, including recovering pure Tramadol from unwanted isomers and achieving 78% solvent recovery on methanol distillation columns, yield structural cost advantages over competitors.

What Could Go Wrong? Key Challenges & Business Risks

Wanbury operates across competitive global chemical markets, exposing it to specific business risks:

  • Raw Material & Geographic Concentration: Heavy dependency on Metformin and Sertraline leaves cash flows sensitive to price competition or changes in therapy adoption. The company’s new product commercialisation strategy aims to mitigate this risk.
  • Geopolitical & Freight Disruptions: Generating 72.91% of sales from export markets exposes Wanbury to international shipping container shortages, freight cost volatility, and regional disruptions (such as geopolitical tensions in West Asia that temporarily affected formulations exports).
  • Refinancing & Leverage Costs: Total debt of ₹215.45 Crores incurs annual finance costs of ₹29.98 Crores. Although borrowing rates dropped to 12.5% per annum, scheduled quarterly repayments require sustained operational cash flow generation.
  • Regulatory Scrutiny: Stricter global oversight by authorities such as the USFDA and DCGI requires continuous compliance expenditure. Sudden notifications on fixed-dose formulations can require rapid portfolio adjustments, as experienced in the pediatric cold segment.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

Wanbury has outlined a clear operational strategy to diversify revenues and expand operating margins through FY 2026-27 and beyond:

  • Four New API Molecules Per Year: Beginning in FY 2026-27, Wanbury intends to commercialise approximately four new API molecules annually to reduce reliance on Metformin and Sertraline. Key molecules in the development pipeline include Quetiapine Fumarate, Dextromethorphan HBr, Rivaroxaban, Imeglimin HCl, Sitagliptin, and Montelukast across anti-diabetic, anti-coagulant, anti-depressant, and gastric ulcer categories.
  • Brownfield Capacity Expansion: Following historical capacity expansions of ~18% in Metformin and ~35% in Sertraline, Wanbury has identified potential for an additional 100 KL of brownfield reactor expansion across its existing Patalganga and Tanuku footprints without requiring greenfield land acquisitions.
  • Formulations Portfolio Pivot: Transitioning the domestic formulations vertical from turnaround mode into scaled brand-building, expanding Wanbury C-RED nationwide and increasing prescription generation among gynecologists and pediatricians.

The Verdict: Strategic Outlook & Conclusion

Wanbury Limited completed a meaningful operational and financial turnaround in FY 2025-26. By lowering its average borrowing rate from 21% to 12.5%, upgrading its enterprise digital core to SAP S/4HANA, debottlenecking chemical reactor throughput, and clearing audits from global regulators (USFDA, ANVISA, MFDS, TGA), the company doubled its net profit margin to 10.72%.

With Net Worth expanding to ₹144.45 Crores, annual operating cash flow reaching ₹31.53 Crores, and a structured pipeline to introduce four new API molecules per year, Wanbury is positioned to consolidate its presence in bulk active ingredients while scaling high-margin domestic branded formulations.

Frequently Asked Questions (FAQs) About Wanbury

Q1: What does Wanbury Limited manufacture, and what are its flagship brands?

Wanbury Limited manufactures bulk Active Pharmaceutical Ingredients (APIs) and finished domestic formulations. In APIs, it specializes in Metformin HCl, Sertraline HCl, Tramadol HCl, Mefenamic Acid, and Anaesthetic APIs. Its primary domestic branded formulations include Wanbury C-RED (liposomal iron for anemia management), Coriminic CPM Drops, and Coriminic NS Nasal Drops (pediatric respiratory relief).

Q2: What were Wanbury’s revenue and net profit figures in FY 2025-26?

In FY 2025-26, Wanbury Limited reported Revenue from Operations of ₹650.27 Crores (an 8.47% increase compared to ₹599.51 Crores in FY 2024-25) and Net Profit After Tax of ₹66.13 Crores (a 116.62% increase compared to ₹30.53 Crores in FY 2024-25).

Q3: Who manages Wanbury Limited, and who are its primary promoters?

Wanbury is led by Mr. K. Chandran (Chairman and Whole-time Director) and Mr. Mohan Kumar Rayana (Whole-time Director). The promoter group comprises Expert Chemicals (India) Private Limited holding 34.36% and Kingsbury Investments Inc. holding 8.66%, representing an aggregate promoter equity stake of 43.02%.

Q4: Where are Wanbury’s manufacturing facilities located, and what is its export share?

Wanbury operates two multi-purpose API manufacturing sites located at Patalganga (Maharashtra) and Tanuku (Andhra Pradesh). International exports account for 72.91% of sales (₹469.42 Crores), serving over 50 countries, including Brazil, the United States, and European Union member states.

Q5: What is Wanbury’s debt profile, credit rating, and net worth position?

As of March 31, 2026, Wanbury’s Total Debt stood at ₹215.45 Crores (comprising ₹147.15 Crores of long-term borrowings and ₹68.30 Crores of short-term borrowings and current debt maturities). Total Equity (Net Worth) expanded to ₹144.45 Crores. The company does not maintain a commercial credit rating programme, funding its operations via bank consortia and secured debentures.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.wanbury.com